Lonnel Coats - Jun 21, 2022 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Role: Director
Signature: /s/ Ariel Hurley, Attorney-in-Fact
Stock symbol: BPMC
Transactions as of: Jun 21, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/30/2022, 09:57 PM
Previous filing: Feb 28, 2022
Next filing: Aug 9, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BPMC	Common Stock	Award	$0	+2.6K	+44.74%	$0.00	8.41K	Jun 21, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BPMC	Stock Option (Right to Buy)	Award	$0	+5.3K		$0.00	5.3K	Jun 21, 2022	Common Stock	$5.3K	$50.64	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2	This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders.

Content

The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders.